Home page Home page

Ambirix
hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)

Package Leaflet: Information for the user


Ambirix, suspension for injection in pre-filled syringe

Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)


Read all of this leaflet carefully before you/your child starts receiving this vaccine because it contains important information for you.


Very rare (These may occur with up to 1 in 10,000 doses of the vaccine):


Please contact your doctor if you have similar side effects.


Side effects that occurred during routine use of Ambirix were as follows:


What Ambirix looks like and contents of the pack


Suspension for injection in a pre-filled syringe.

Ambirix is a white, slightly milky liquid presented in a glass 1 ml pre-filled syringe.

Ambirix is available in packs of 1 and 10 pre-filled syringes (with or without needles) and in pack sizes of 50 pre-filled syringes without needles.

Not all pack sizes may be marketed.


Marketing Authorisation Holder and Manufacturer


GlaxoSmithKline Biologicals s.a. Rue de l’Institut 89

B-1330 Rixensart Belgium


For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:


België/Belgique/Belgien GlaxoSmithKline Pharmaceuticals SA/NV Tél/Tel: + 32 10 85 52 00

Lietuva

GlaxoSmithKline Biologicals SA Tel. +370 80000334


България

GlaxoSmithKline Biologicals SA

Тел.: +359 80018205

Luxembourg/Luxemburg GlaxoSmithKline Pharmaceuticals SA/NV Tél/Tel: + 32 10 85 52 00


Česká republika GlaxoSmithKline s.r.o. Tel: + 420 2 22 00 11 11

cz.info@gsk.com

Magyarország

GlaxoSmithKline Biologicals SA

Tel.: +36 80088309


Danmark

GlaxoSmithKline Pharma A/S

Tlf: + 45 36 35 91 00

dk-info@gsk.com

Malta

GlaxoSmithKline Biologicals SA

Tel: +356 80065004


Deutschland

GlaxoSmithKline GmbH & Co. KG

Tel: + 49 (0)89 360448701

produkt.info@gsk.com

Nederland GlaxoSmithKline BV Tel: + 31 (0)33 2081100


Eesti

GlaxoSmithKline Biologicals SA

Tel: +372 8002640

Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00


Ελλάδα

GlaxoSmithKline Μονοπρόσωπη A.E.B.E. Tηλ: + 30 210 68 82 100

Österreich

GlaxoSmithKline Pharma GmbH. Tel: + 43 1 970 75-0

at.info@gsk.com

España GlaxoSmithKline, S.A. Tel: + 34 900 202 700

es-ci@gsk.com

Polska

GSK Services Sp. z o.o. Tel.: + 48 (22) 576 9000


France

Laboratoire GlaxoSmithKline

Tél: + 33 (0) 1 39 17 84 44

diam@gsk.com


Hrvatska

GlaxoSmithKline Biologicals SA

Tel.: +385 800787089

Portugal

Smith Kline & French Portuguesa - Produtos

Farmacêuticos, Lda. Tel: + 351 21 412 95 00

FI.PT@gsk.com


România

GlaxoSmithKline Biologicals SA

Tel: +40 800672524


Ireland

GlaxoSmithKline (Ireland) Ltd

Tel: + 353 (0)1 495 5000

Slovenija

GlaxoSmithKline Biologicals SA

Tel: +386 80688869


Ísland

Vistor hf.

Sími: +354 535 7000

Slovenská republika GlaxoSmithKline Biologicals SA Tel: +421 800500589


Italia

GlaxoSmithKline S.p.A.

Tel: + 39 (0)45 77411 11

Suomi/Finland

GlaxoSmithKline Oy

Puh/Tel: + 358 (0)10 30 30 30


Κύπρος

GlaxoSmithKline Biologicals SA

Τηλ: +357 80070017

Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00

info.produkt@gsk.com


Latvija

GlaxoSmithKline Biologicals SA

Tel: +371 80205045

United Kingdom (Northern Ireland) GlaxoSmithKline Biologicals SA Tel: +44(0)800 221441

customercontactuk@gsk.com


This leaflet was last revised in


---------------------------------------------------------------------------------------------------------------------


The following information is intended for healthcare professionals only:


Upon storage, a fine white deposit with a clear colourless layer above may be observed.


The vaccine should be re-suspended before use. When re-suspended, the vaccine will have a uniform hazy white appearance.


Re-suspension of the vaccine to obtain a uniform hazy white suspension


The vaccine should be re-suspended following the steps below.

    1. Hold the syringe upright in a closed hand.

    2. Shake the syringe by tipping it upside down and back again.

    3. Repeat this action vigorously for at least 15 seconds.

    4. Inspect the vaccine again:

      1. If the vaccine appears as a uniform hazy white suspension, it is ready to use – the appearance should not be clear.

      2. If the vaccine still does not appear as a uniform hazy white suspension - tip upside

down and back again for at least another 15 seconds - then inspect again.


The vaccine should be inspected visually for any foreign particulate matter and/or abnormal physical appearance prior to administration. In the event of either being observed, do not administer the vaccine.


Any unused medicinal product or waste material should be disposed of in accordance with local requirements.